Sanjivani Paranteral Ltd

Sanjiv.Parant. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sanjivani Paranteral Ltd

₹ 233 -1.19%
12 Jun - close price
sanjivani.co.in BSE: 531569
About

Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]

Key Points

Business Overview:[1][2]
SPL is a WHO-GMP, DIGEMID, and DDA-certified pharmaceutical company specializing in high-quality parenteral and oral solid formulations. It serves key therapeutic areas including CNS, CVS, antibiotics, urology, anesthetics, gastroenterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants, and vitamin supplements.

Website BSE
  • Market Cap ₹ 277 Cr.
  • Current Price ₹ 233
  • High / Low ₹ 397 / 172
  • Stock P/E 34.2
  • Book Value ₹ 32.0
  • Dividend Yield 0.00 %
  • ROCE 28.5 %
  • ROE 24.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company's working capital requirements have reduced from 25.1 days to 14.7 days

Cons

  • Stock is trading at 7.29 times its book value
  • Promoter holding is low: 28.9%
  • Debtor days have increased from 59.2 to 86.8 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Mar 2024 Sep 2024 Dec 2024 Mar 2025
14.96 12.86 18.13 17.35 18.18
12.99 10.70 15.28 14.80 15.57
Operating Profit 1.97 2.16 2.85 2.55 2.61
OPM % 13.17% 16.80% 15.72% 14.70% 14.36%
0.25 0.05 0.39 0.31 0.43
Interest 0.08 0.09 0.18 0.19 0.20
Depreciation 0.24 0.24 0.15 0.16 0.18
Profit before tax 1.90 1.88 2.91 2.51 2.66
Tax % 13.16% 33.51% 21.31% 24.30% 17.29%
1.65 1.26 2.30 1.90 2.19
EPS in Rs 1.65 1.08 1.97 1.60 1.84
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
54.41 70.10
46.18 59.76
Operating Profit 8.23 10.34
OPM % 15.13% 14.75%
0.52 1.22
Interest 0.25 0.59
Depreciation 0.93 0.62
Profit before tax 7.57 10.35
Tax % 18.63% 21.84%
6.17 8.09
EPS in Rs 5.28 6.81
Dividend Payout % 0.00% 7.34%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 29%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 31%
Stock Price CAGR
10 Years: 31%
5 Years: 103%
3 Years: 68%
1 Year: 33%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 25%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
Equity Capital 11.68 11.88
Reserves 16.21 26.11
0.97 8.14
14.55 32.07
Total Liabilities 43.41 78.20
9.94 20.64
CWIP 0.00 19.11
Investments 0.00 0.00
33.47 38.45
Total Assets 43.41 78.20

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
-10.70 12.40
-12.21 -20.11
23.16 8.66
Net Cash Flow 0.24 0.94

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
Debtor Days 31.53 86.85
Inventory Days 124.70 94.77
Days Payable 73.56 137.51
Cash Conversion Cycle 82.67 44.11
Working Capital Days 35.55 14.74
ROCE % 28.46%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
27.35% 27.35% 27.35% 29.88% 31.70% 32.34% 32.34% 27.67% 27.67% 27.67% 27.67% 28.87%
16.50% 16.50% 16.50% 14.23% 11.89% 8.16% 6.01% 9.71% 9.36% 6.26% 6.26% 6.15%
56.14% 56.14% 56.14% 55.89% 56.40% 59.51% 61.65% 62.62% 62.98% 66.08% 66.09% 64.97%
No. of Shareholders 4,8484,8264,8454,8874,7584,5004,5004,9116,1666,7316,6186,447

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls